Lung cancer prevention, management, and emerging therapies

Defining the Lung Cancer Problem 1 Lung cancer is the leading cause of cancer death in the world. It kills almost as many Americans as cancers of the breast, prostate, colon, rectum, pancreas, and 2 kidney combined, and accounts for 28.6% of all US cancer deaths. With an increase in the 5-year relative survival rate from 13%

Tabla de contenido

Molecular pathology of lung cancer: Alejandro Corvalan and Ignacio Wistuba Tumor microenvironment: Tonya C. Walser, Jane Yanagawa, Edward Garon, Jay M. Lee, Steven Dubinett Racial and ethnic diversity in lung cancer: Carol J. Etzel, Sumesh Kachroo Pharmacogenetics of lung cancer: Xifeng Wu, Jian Gu Lung cancer prevention Nir Peled, Robert L. Kieth, Fred Hirsch Adjuvant and neoadjuvant therapy of non-small cell lung cancer: Katherine Pisters Chemoradiotherapy for inoperable non-small cell lung cancer: James Cox and David J. Stewart Management of advanced non-small cell lung cancer- front line treatment: William N. William Jr. and David J. Stewart Chemotherapy in previously-treated patients with non-small cell lung cancer: Frank V. Fossella Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer: Paul Wheatley-Price and Frances A, Shepherd Angiogenesis inhibitors in lung cancer : Leora Horn and Alan Sandler Other molecular targeted agents in non-small cell lung cancer: Benjamin Besse and Jean Charles Soria Vaccine therapy for lung cancer: John Nemunaitis and Jack Roth Gene-based therapies for lung cancer: John Nemunaitis and Jack Roth Lung cancer resistance to chemotherapy: David J. Stewart Small cell carcinoma: Emer Hanrahan and Bonnie Glisson Mesothelioma: Mary Frances McAleer, Reza J. Mehran, and Anne Tsao Advances in oncology clinical research statistical and study design methodologies: B. Nebiyou Bekele Palliativecare for patients with lung cancer: David Hui and Eduardo Bruera The future of lung cancer: Sophie Sun, Joan H. Schiller, Monica Spinola, John Minna